Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TRASTUZUMAB-DTTB for Neoplasm malignant: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 8 adverse event reports in the FDA FAERS database where TRASTUZUMAB-DTTB was used for Neoplasm malignant.

Most Reported Side Effects for TRASTUZUMAB-DTTB

Side Effect Reports % Deaths Hosp.
Diarrhoea 150 30.2% 1 133
Product use in unapproved indication 89 17.9% 4 83
Nausea 66 13.3% 0 54
Pyrexia 65 13.1% 1 62
Off label use 63 12.7% 3 56
Anaemia 61 12.3% 0 55
Vomiting 46 9.3% 0 38
Hypokalaemia 43 8.7% 0 43
Chills 40 8.1% 1 22
Dyspnoea 37 7.4% 0 21
Acute kidney injury 31 6.2% 0 31
Abdominal pain 26 5.2% 0 21
General physical health deterioration 26 5.2% 3 23
Fatigue 25 5.0% 0 19
Headache 25 5.0% 0 16

Other Indications for TRASTUZUMAB-DTTB

Breast cancer (143) Oesophageal adenocarcinoma (98) Breast cancer female (61) Her2 positive breast cancer (59) Product used for unknown indication (38) Breast cancer metastatic (34) Her2 positive gastric cancer (10) Invasive ductal breast carcinoma (8) Adenocarcinoma gastric (6) Breast neoplasm (5)

Other Drugs Used for Neoplasm malignant

PALBOCICLIB (1,996) CAPECITABINE (1,493) PEMBROLIZUMAB (1,135) PACLITAXEL (984) CARBOPLATIN (977) NIVOLUMAB (947) OXALIPLATIN (823) PAZOPANIB (716) CYCLOPHOSPHAMIDE (685) FLUOROURACIL (676)

Related Pages

TRASTUZUMAB-DTTB Full Profile All Neoplasm malignant Drugs TRASTUZUMAB-DTTB Demographics TRASTUZUMAB-DTTB Timeline